SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma

Masum Saini(Regional Centre for Biotechnology), Sam J. Mathew(Regional Centre for Biotechnology)

Cell Death and Disease

February 14, 2018

10.1038/s41419-018-0261-2

Cited by 30

Related Papers

Musculoskeletal defects associated with myosin heavy chain‐embryonic loss of function are mediated by the YAP signaling pathway

|EMBO Molecular Medicine|2023|12

Zeb1 and Tle3 are <i>trans</i> ‐factors that differentially regulate the expression of myosin heavy chain‐embryonic and skeletal muscle differentiation

|The FASEB Journal|2023|8

Tumor suppressor candidate 1 (TUSC1) drives oxidative phosphorylation and tumor cell death in colorectal cancer

|APOPTOSIS|2026|0